“This discovery provides new insights into the mechanisms of the disease and identifies galectin-3 as a potential future therapeutic target,” says Lluís Camprubí-Ferrer, one of the study’s lead authors and a postdoctoral researcher at Lund University.
The study is published in the journal Proceedings of the National Academy of Sciences.
Galectin-3 actively reshapes amyloid plaques
Alzheimer’s disease (AD) is characterized by accumulations of beta-amyloid (Aβ) in the brain. These proteins clump together to form plaques. In a previous study, the research team at Lund University showed for the first time that the protein galectin-3 increases in the brains of people with Alzheimer’s disease and that removing the protein decreased inflammation in the brain. In this new study, the researchers have shown the direct relationship between galectin-3 and Aβ plaques.